All for Joomla The Word of Web Design
November Sunday

Cuba approves clinical trial for its second vaccine candidate against Covid-19

HAVANA, Cuba, Oct 28 (ACN) Cuba's Center for State Control of Medicines, Equipment and Medical Devices (CECMED) certified the clinical trial phase I for the vaccine candidate against Covid-19, Soberana 02, the Finlay Institute reported.

'We are pleased to inform that CECMED approved the clinical trial phase I of the vaccine candidate Soberana 02, a mixed vaccine platform with backgrounds at the Finlay Institute, tweeted the institution specialized in the creation of vaccines.

'A know-how distinguishes us in the field of #preventive vaccines,' the message adds.

Recently, the director of the Finlay Institute, Vicente Verez, affirmed in an interview with the Granma newspaper that Soberana 02 is an innovative drug, as it has no precedents among all those developed to fight against the SARS-CoV-2 coronavirus, which causes Covid-19.

As explained by the expert on that occasion, the novelty of this new candidate consists of being a mixed vaccine, in which the virus antigen, the receptor-binding domain (RBD), is chemically linked to the tetanus toxoid.

'We hope that the immunity of Soberana 02 reaches the mucous membrane of the respiratory tract to prevent the entry of the virus, and it will be the vaccine candidate that we will propose to apply in the pediatric population,' Verez stressed.




Add comment

No se admiten ofensas, frases vulgares ni palabras obscenas.
Nos reservamos el derecho de no publicar los comentario que incumplan con las normas de este sitio

Security code